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OVERCOMING 
BIOLOGICAL BARRIERS:
PEPTIDE  NANOTUBES 
FOR DRUG DELIVERY
Biological barriers
• Biological barriers inhibit drug delivery 
throughout the body
• For efficient drug delivery, drugs must be able 
to reach their target site of action
• The blood brain barrier is very problematic for 
drug delivery
• Large gap in adequate care for patients for 
particular diseases: brain tumors, Parkinson's, 
Alzheimer's
CRS. 2015. Controlled release society. [ONLINE] Available at: http://www.crsaustralia.org/?page_id=971. [Accessed 16 April 2017].
The blood brain barrier
For Transmembrane diffusion of small 
molecules: <400 Daltons and high lipid 
solubility
Approaches to bypassing this barrier:
• Disruption of the blood brain barrier tight 
junctions (detergents or ultrasound)
• Receptor mediated transcytosis – engage 
cell-surface receptors over expressed by 
brain cells.
• Adsorptive endocytosis of nanoparticles
Jonathan C.H. Choi . 2016. Jonathan C.H. Choi Research Group. [ONLINE] Available at: http://www.bme.cuhk.edu.hk/jchchoi/r_SHIAE14-16.php. [Accessed 16 April 2017].
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• Ultra short peptide structure 
consisting of two amino acids
• Phenylalanine-Phenylalanine
• Molecular weight of 312.36 Daltons
• Relatively easy manufacture process 
due to the short length – peptides 
become increasingly difficult to 
manufacture at high purities with 
increasing chain length
Peptide structure
Self assembled peptide nanotubes
B: Adsorptive endocytosis (Previously 
demonstrated for nanotube structures)
Astrocyte
Characterising the assembled 
secondary structure
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Circular dichroism spectra for assembled peptide 
nantotube structures:
• Large positive peak ~ 217 nm
• Characteristic of β-sheet assembly in peptides
• Useful to confirm presence of peptide nanotubes in 
absence of environmental microscope
Measuring zeta potential
pH (n=3) Mean Zeta Potential (mV)
7.4 -21.10(±0.49)
5.5 -13.57(±2.37)
• Particle charge is a key consideration when 
considering formulation of any nanoparticle
• Unfavourable charge pairing will lead to the 
repelling of the drug cargo from the nanoparticle
• Extremes of either positive or negative charge 
unfavourable for delivering across cell layers 
because it can lead to entrapment
Water World. 2016. ONLINE ZETA POTENTIAL MEASUREMENT PROVIDES WATER TREATMENT CONTROL, COST REDUCTION. [ONLINE] Available at: http://www.waterworld.com/articles/print/volume-
30/issue-10/features/automation-technology/online-zeta-potential-measurement-provides-water-treatment-control-cost-reduction.html. [Accessed 16 April 2017].
Encapsulation of Rhodamine B
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• Instead of beginning encapsulation and 
permeation studies with a drug, a 
fluorescent molecule is used for ease of 
screening
• Rhodamine B is chosen as a tracer 
molecule due to the previous zeta 
potential data, rhodamine should be 
positively charged at pH during the 
assembly process
• Rhodamine B is added while the peptide 
nanotubes are self assembling and are 
spontaneously incorporated into the 
tubes
• A maximum of 56 % encapsulation 
efficiency was observed
In-vitro blood brain 
barrier model
• Transwell inserts used to grow a brain 
endothelial cell layer on
• Semi-porous membrane containing 
defined pore size (0.4 micron)
• Cell layer grown on insert membrane –
creates two separate chambers 
separated by a brain endothelial cell 
layer (hCMEC/D3 Cell)
• Nanotube suspensions loaded with a 
fluorescent marker can be loaded into 
top chamber
• Validate using TEER
Brunswick laboratories. 2016. Caco-2 Permeability Screening Assay (unidirectional/bidirectional). [ONLINE] Available at: https://brunswicklabs.com/capabilities/clinical-study/adme-tox-studies/caco-2-permeability-screening/. 
[Accessed 16 April 2017].
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Permeation across model
• At time zero peptide nanotube suspension 
loaded with rhodamine b is added to the top 
chamber of the transwell insert
• The bottom chamber is sampled over time 
and the fluorescence intensity of rhodamine b 
at 562/583 nm excitation/emission 
wavelengths is recorded
• Peptide nanotubes transport rhodamine over 
the cell monolayer and then begin to de-
assemble once they have reached the bottom 
compartment and are no longer in a peptide 
monomer saturated solution
• After 4 hours 2.4% of the total dose had 
crossed, which is reasonable considering the 
short time point
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Biocompatibility 
studies
Haemolysis of equine erythrocytes:
• Peptide nanotubes are incubated with 
horse red blood cells
• The percentage of red blood cells lysed 
can be calculated by measuring 
absorbance
• Gives an indicator of how compatible the 
treatments would be as an injectable
Percentage of remaining viable NCTC 929 cells following 6-hour
treatment with a range of peptide nanotube suspension concentrations
using a MTS assay. Key: black column:. NS: no significant difference
(P≥0.05), *: P<0.01 significant difference between percentage viability of
peptide nanotube treated cells and negative control.
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LIVE/DEAD® stain of NCTC 929 cells following 6-hour treatment
with peptide nanotube suspension. Live cells are stained green and
dead cells are stained red. Scale bar represents 200 µm.
Conclusions
• Phenylalanine-phenylalanine peptides can self assemble into nanotube structures which can 
encapsulate fluorescent markers
• Preliminary studies have shown they  have high biocompatibility and can permeate an in 
vitro blood brain barrier model
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